ACOG Latest Press Releases

-- October 13, 2026 --

Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL Business Wire 8:30 AM

-- October 6, 2026 --

Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress Business Wire 8:30 AM

-- October 2, 2026 --

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:06 PM

-- October 1, 2026 --

Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL(Benzgalantamine) Use in Long-Term Care Business Wire 8:30 AM

-- September 9, 2026 --

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 6:00 PM

-- September 1, 2026 --

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- August 13, 2026 --

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update Business Wire 4:05 PM

-- August 3, 2026 --

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update Business Wire 8:30 AM

-- July 29, 2026 --

Alpha Cognition Receives European Patent Covering ZUNVEYL for the Treatment of Mild-to-Moderate Alzheimer's Disease Business Wire 8:30 AM

-- July 10, 2026 --

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit Business Wire 8:30 AM

-- June 23, 2026 --

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board Business Wire 8:30 AM

-- June 16, 2026 --

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL in Patients with Mild to Moderate Alzheimer's Disease Business Wire 8:30 AM

-- June 9, 2026 --

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL in Alzheimer's Disease Business Wire 8:00 AM

Market Data Delayed 15 Minutes